METTL9, methyltransferase like 9, 51108

N. diseases: 24; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder
0.100 GeneticVariation disease GWASCAT Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. 30718901 2019
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder
0.100 GeneticVariation disease GWASCAT Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways. 29662059 2018
Autosomal dominant retinitis pigmentosa
0.030 Biomarker disease BEFREE Mutations in the pre-mRNA splicing factor, RP9 (also known as PAP1), predispose autosomal dominant retinitis pigmentosa (adRP) with an early onset and severe vision loss. 28216641 2017
Autosomal dominant retinitis pigmentosa
0.030 Biomarker disease BEFREE PAP-1 has been identified by us as a Pim-1-binding protein and has recently been implicated as the defective gene in RP9, one type of autosomal dominant retinitis pigmentosa (adRP). 15541726 2005
Autosomal dominant retinitis pigmentosa
0.030 Biomarker disease BEFREE PAP-1 has recently been implicated as the defective gene in RP9, one type of autosomal dominant retinitis pigmentosa (adRP). 15474994 2004
Diabetes Mellitus, Non-Insulin-Dependent
0.020 AlteredExpression disease BEFREE However, reduced LPIN1 and PAP1 activity has been described in participants with type 2 diabetes. 27344312 2016
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.020 Biomarker group BEFREE Here we report for the first time that Psora-4, PAP-1 and clofazimine, three distinct membrane-permeant inhibitors of Kv1.3, induce death by directly targeting the mitochondrial channel in multiple human and mouse cancer cell lines. 22496117 2012
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.020 Biomarker group BEFREE Here we report for the first time that Psora-4, PAP-1 and clofazimine, three distinct membrane-permeant inhibitors of Kv1.3, induce death by directly targeting the mitochondrial channel in multiple human and mouse cancer cell lines. 22496117 2012
Diabetes Mellitus, Non-Insulin-Dependent
0.020 AlteredExpression disease BEFREE Here, we studied cardiac PAP(1) activity and lipin expression ex vivo in 8-month-old Zucker diabetic fatty (ZDF) rats and humans with type 2 diabetes mellitus undergoing open heart surgery for coronary bypass grafting. 19799857 2009
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.020 GeneticVariation group BEFREE This method was applied to 40 archival smears from ten cervical cancer patients (selected from a group of 200 patients) which had a history of 3-6 smears with the first smear being Pap 1 or 2 taken at least 5 years before cancer was diagnosed. 10780521 2000
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.020 GeneticVariation group BEFREE This method was applied to 40 archival smears from ten cervical cancer patients (selected from a group of 200 patients) which had a history of 3-6 smears with the first smear being Pap 1 or 2 taken at least 5 years before cancer was diagnosed. 10780521 2000
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.010 Biomarker phenotype BEFREE Inhibition of either microglial activation or CCR2 abolished the PAP-I-induced hyperalgesia. 31744864 2020
CUI: C0027796
Disease: Neuralgia
Neuralgia
0.010 Biomarker phenotype BEFREE Thus, PAP-I mediates the neuron-microglial crosstalk after peripheral nerve injury, and contributes to the maintenance of neuropathic pain.<b>SIGNIFICANCE STATEMENT</b>Neuropathic pain is maladaptive pain condition and the maintaining mechanism is largely unclear. 31744864 2020
CUI: C0030193
Disease: Pain
Pain
0.010 Biomarker phenotype BEFREE Thus, PAP-I mediates the neuron-microglial crosstalk after peripheral nerve injury, and contributes to the maintenance of neuropathic pain.<b>SIGNIFICANCE STATEMENT</b>Neuropathic pain is maladaptive pain condition and the maintaining mechanism is largely unclear. 31744864 2020
CUI: C0751213
Disease: Tactile Allodynia
Tactile Allodynia
0.010 Biomarker phenotype BEFREE Intrathecal delivery of PAP-I enhanced sensory hyperalgesia, whereas PAP-I deficiency by either gene knockout or antibody application alleviated tactile allodynia at the maintenance phase after SNI. 31744864 2020
CUI: C0009319
Disease: Colitis
Colitis
0.010 AlteredExpression disease BEFREE PAP-1 also reduced the expression of Kv1.3, iNOS, NLRP3, caspase-1p20 and IL-1β on macrophages in colitis mice. 31351364 2019
CUI: C0740391
Disease: Middle Cerebral Artery Occlusion
Middle Cerebral Artery Occlusion
0.010 Biomarker disease BEFREE We studied microglial Kv1.3 expression using electrophysiology and immunohistochemistry, and evaluated PAP-1 in hypoxia-exposed organotypic hippocampal slices and in middle cerebral artery occlusion (MCAO) with 8 days of reperfusion in both adult male C57BL/6J mice (60 min MCAO) and adult male Wistar rats (90 min MCAO). 29468176 2018
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.010 Biomarker phenotype BEFREE In the same mouse model, PAP-1 reduces astrogliosis and microglial infiltration.PAP-1 also reduces tumor cell invasion. 29769580 2018
CUI: C2363774
Disease: Neutrophilic asthma
Neutrophilic asthma
0.010 Biomarker disease BEFREE In this study, we investigate the effects of PAP-1, a selective inhibitor of Kv1.3 channel, on the treatment of the neutrophilic asthma model. 30077824 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.010 Biomarker group BEFREE By synthesizing new, mitochondria-targeted derivatives (PAPTP and PCARBTP) of PAP-1, a specific membrane-permeant Kv1.3 inhibitor, we have recently provided evidence that both drugs acting on mitoKv1.3 are able to induce apoptosis and reduce tumor growth <i>in vivo</i> without affecting healthy tissues and cells. 29034212 2017
CUI: C1301509
Disease: Severe visual impairment
Severe visual impairment
0.010 GeneticVariation disease BEFREE Mutations in the pre-mRNA splicing factor, RP9 (also known as PAP1), predispose autosomal dominant retinitis pigmentosa (adRP) with an early onset and severe vision loss. 28216641 2017
CUI: C0011847
Disease: Diabetes
Diabetes
0.010 AlteredExpression disease BEFREE Consistent with the findings in experimental animals, human atrial tissue displayed PAP(1) activity that was 33% lower in those having diabetes than in non-diabetic controls. 19799857 2009
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.010 AlteredExpression group BEFREE Consistent with the findings in experimental animals, human atrial tissue displayed PAP(1) activity that was 33% lower in those having diabetes than in non-diabetic controls. 19799857 2009
CUI: C0023787
Disease: Lipodystrophy
Lipodystrophy
0.010 Biomarker disease BEFREE Our results establish the three mammalian lipin proteins as PAP1 enzymes and explain the biochemical basis for lipodystrophy in the lipin-1-deficient fld mouse. 17158099 2007
CUI: C1867300
Disease: RETINITIS PIGMENTOSA 9
RETINITIS PIGMENTOSA 9
0.010 GeneticVariation disease BEFREE We used the same splicing assay to examine the activities of two mutant forms of PAP-1 found in RP9 patients. 15474994 2004